Specialty Pharmacy

Quest Diagnostics Study Finds Physicians Lack the Time and Tools to Discover Hidden Risks in Patients with Chronic Conditions

SECAUCUS, N.J., May 23, 2018 /PRNewswire/ — The vast majority of primary care physicians don’t have the time or tools to adequately address the needs of their patients with multiple chronic conditions, leaving some patients to struggle with health-related social and behavioral issues on their own, according to new research …

Read More »

Cytox and Mayo Clinic Collaborate to Evaluate Novel Genetic Based Approaches for Assessing Alzheimer’s Risk

OXFORD, England & MANCHESTER, England–(BUSINESS WIRE)–Cytox, a precision medicine front-runner which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s and other neurological diseases, has announced it has entered into a research collaboration with Mayo Clinic to test current and develop new proprietary algorithms …

Read More »

Biosimilars Could Facilitate Early Access to Life Changing Biological Treatments for Patients

BALTIMORE–(BUSINESS WIRE)–At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring …

Read More »

Janssen Halts Development of its BACE Inhibitor for Alzheimer’s Disease Due to Liver Safety Concerns

Titusville, United States, May 17, 2018 – At Janssen, the safety and well-being of people who participate in our clinical trials are of utmost importance to us. For the past several years, we have been studying an investigational drug called a BACE inhibitor. The goal of this research is to slow …

Read More »

FDA Approves Aimovig as First Calcitonin Gene-Related Peptide (CGRP) Blocker for Migraine Prevention

THOUSAND OAKS, Calif., May 17, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R) …

Read More »

Pfizer’s Lyrica Oral Solution CV Meets Primary Endpoint in Late-Stage Trial in Pediatric Epilepsy

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today positive top-line results of a Phase 3 study examining the use of LYRICA® (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age. Results showed that adjunctive treatment with …

Read More »

FDA Grants Priority Review to Insmed’s ALIS in NTM Lung Disease Caused by MAC

BRIDGEWATER, N.J., May 16, 2018 (GLOBE NEWSWIRE) — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) for adult …

Read More »

Diplomat Launches CastiaRx, Industry-Leading Specialty Benefit Manager

FLINT, Mich., April 30, 2018 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), has unveiled CastiaRx to respond to industry demand for a leader in specialty benefit management. CastiaRx unites the full-service pharmacy benefit manager (PBM) capabilities of recently acquired LDI Integrated Pharmacy Services and National Pharmaceutical Services with Diplomat’s specialty …

Read More »

Endo to Acquire Specialty Pharmaceutical Company Somerset Therapeutics for $190 Million

DUBLIN, April 26, 2018 /PRNewswire/ — Endo International plc (NASDAQ: ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India based affiliate Wintac Limited, which operates as Somerset Therapeutics’ contract …

Read More »

Eisai and Boston University Partner to Study the Effects of Alzheimer’s Disease-Associated Genetic Variants on Brain

ANDOVER, Mass. and BOSTON, Jan. 30, 2018 /PRNewswire/ — Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia. Recent discoveries regarding the genetic underpinnings of Alzheimer’s disease (AD), suggest …

Read More »